Award Data

DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step in the recruitment of white blood cells to sites of inflammation. Vasoocclusion is precipitated by a P- selectin-mediated adhesion of sickled red ...

DESCRIPTION (provided by applicant): Organophosphorus (OPs) compound are potent neurotoxic chemicals that are widely used in medicine, industry and agriculture; most notably as insecticides. The neurotoxicity which is primarily a result of AChE inhibition, may take the form of cholinergic crisis and death as a consequence of acute exposure or psychiatric symptoms and delayed neuropathy following c ...

DESCRIPTION (provided by applicant): A Tracked MR Hardware/Software System for Motion Robust Pediatric Magnetic Resonance Imaging This research aims to develop improved motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that both aids in the diagnosis of individual subjects, guides their clinical care, and provides insights into the mechanisms ...

DESCRIPTION (provided by applicant): The goal of this project is to develop and test the feasibility of an eyetracking system for assessment of language comprehension in people with stroke and brain injury. Most people who have had a stroke or brain injury have deficits that may impair their ability to respond, or to respond correctly, when traditional tests of linguistic comprehension are adminis ...

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. This proposal displays preliminary results showing specific decorporation agents for Sr(II) that do not bind Ca(II); Sr(II) is ...

DESCRIPTION (provided by applicant): Malaria is a major threat to world health. Each year, there are 350-500 million clinical cases and greater than one million deaths due to malaria, primarily of children in sub- Saharan Africa. There is an urgent need for a safe and effective malaria vaccine and the development of such a vaccine is a global health priority. An abundance of data in animal models ...

DESCRIPTION (provided by applicant): The antiviral market is experiencing considerable growth with a predicted market value that is expected to double in size to more than 44B by 2010. Among the drugs that are experiencing considerable growth are those targeted to HSV-1 and -2. Anti-herpes product sales in 2007 in the United States for all indications were in excess of 2 and are projected to rea ...

DESCRIPTION (provided by applicant): Mycobacterium avium complex (MAC) and M. abscessus (MAB) are the two most common nontuberculous mycobacteria (NTM) that cause human disease, and the incidence of NTM infections has been increasing worldwide. Both the organisms are generally resistant to standard antimybacterial drugs and other antibiotics. Hence, there is an critical need for new antimicrobial ...

DESCRIPTION (provided by applicant): Recent reports indicate that a new strain of adenovirus serotype 14 (Ad14) is causing frequent acute respiratory disease (ARD) and deaths in otherwise health people. The overall goal of this SBIR is to generate a vaccine that can protect against Ad14 infection and disease. Our hypothesis is that an Ad14 vector particle that is made non-replicating by means of a ...

N/A